<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8226">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900704</url>
  </required_header>
  <id_info>
    <org_study_id>SPC-SER120-DB4-201301</org_study_id>
    <nct_id>NCT01900704</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4</brief_title>
  <acronym>DB4</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serenity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Serenity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of SER120 nasal spray formulations in patients with
      nocturia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of nocturic episodes at the end of treatment compare to prior to treatment</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes on the treatment</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>SER120 750 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 750 ng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SER120 1500 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 1500 ng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 750 ng</intervention_name>
    <description>SER120 750 ng</description>
    <arm_group_label>SER120 750 ng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 1500 ng</intervention_name>
    <description>SER120 1500 ng</description>
    <arm_group_label>SER120 1500 ng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female 50 years or older

          -  Nocturia of 6 or more months duration averaging greater than 2 nocturic episodes per
             night

        Exclusion Criteria:

          -  CHF

          -  Diabetis Insipidus

          -  Renal insufficiency

          -  Hepatic insufficiency

          -  Incontinence

          -  Illnesses requiring systemic steroids

          -  Malignancy within the past 5 years

          -  Sleep apnea

          -  Nephrotic syndrome

          -  Unexplained pelvic mass

          -  Urinary bladder neurological dysfunction

          -  Urinary bladder surgery or radiotherapy

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Serenity R &amp; D</name>
      <address>
        <city>New City</city>
        <state>New York</state>
        <zip>10956</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seymour Fein, MD</last_name>
      <phone>845-639-6760</phone>
      <phone_ext>17</phone_ext>
      <email>sfein@serenitypharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
